Anupam Rasayan India Ltd.
ANURASCommodities filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
19 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 19 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210824 | 2021-06-30 | yes | |
| TRANSCRIPT | 20220517 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220729 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221101 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230130 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230508 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230805 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231111 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240215 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240527 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240820 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241120 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250219 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250528 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250819 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251025 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260219 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260530 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260820 | 2026-06-30 | yes |
ANURAS
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,177.20 |
| 52-week range | 1064.7 – 1376.0 |
| Return 1M | -6.91% |
| Return 3M | -7.68% |
| Return 1Y | 6.02% |
| Return 3Y | 33.34% |
| Return 5Y | 55.13% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 655.00 |
| Other income | 13.00 |
| Total income | 668.00 |
| Cost of materials consumed | 354.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -69.00 |
| Employee benefit expense | 65.00 |
| Finance costs | 49.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.59 | 0.00 |
| institutions foreign | 0.08 | 0.01 |
| institutions domestic | 0.00 | 0.00 |
| mutual funds | 0.00 | 0.00 |
| public | 0.41 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 19 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 386.00 | 383.00 | 480.00 | 386.00 | 392.00 | 296.00 | 401.00 | 254.00 | 294.00 | 390.00 | 500.00 | 486.00 | 731.00 | 512.00 | 636.00 | 655.00 |
| Other income | -3.00 | 6.00 | 24.00 | 12.00 | 3.00 | 2.00 | 12.00 | 6.00 | 2.00 | -4.00 | 6.00 | 5.00 | 8.00 | 2.00 | 3.00 | 13.00 |
| Total income | 383.00 | 389.00 | 504.00 | 399.00 | 396.00 | 298.00 | 413.00 | 260.00 | 296.00 | 387.00 | 506.00 | 491.00 | 739.00 | 515.00 | 639.00 | 668.00 |
| Cost of materials consumed | 183.00 | 155.00 | 221.00 | 230.00 | 187.00 | 147.00 | 129.00 | 183.00 | 199.00 | 273.00 | 283.00 | 361.00 | 425.00 | 270.00 | 386.00 | 354.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | -2.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -22.00 | 14.00 | 15.00 | -67.00 | -25.00 | -46.00 | 59.00 | -81.00 | -90.00 | -116.00 | -45.00 | -119.00 | 51.00 | 4.00 | -54.00 | -69.00 |
| Employee benefit expense | 18.00 | 20.00 | 16.00 | 19.00 | 19.00 | 21.00 | 17.00 | 17.00 | 18.00 | 20.00 | 18.00 | 20.00 | 17.00 | 18.00 | 31.00 | 65.00 |
| Finance costs | 16.00 | 14.00 | 20.00 | 18.00 | 20.00 | 25.00 | 26.00 | 22.00 | 27.00 | 32.00 | 31.00 | 36.00 | 36.00 | 35.00 | 42.00 | 49.00 |
| Depreciation and amortisation | 18.00 | 18.00 | 19.00 | 19.00 | 20.00 | 20.00 | 21.00 | 21.00 | 22.00 | 29.00 | 31.00 | 31.00 | 32.00 | 34.00 | 43.00 | 56.00 |
| Other expenses | 102.00 | 92.00 | 110.00 | 103.00 | 104.00 | 94.00 | 103.00 | 82.00 | 87.00 | 89.00 | 100.00 | 97.00 | 104.00 | 93.00 | 136.00 | 143.00 |
| Total expenses | 316.00 | 313.00 | 401.00 | 321.00 | 325.00 | 262.00 | 355.00 | 244.00 | 262.00 | 327.00 | 418.00 | 428.00 | 664.00 | 455.00 | 583.00 | 598.00 |
| Profit before exceptional items and tax | 67.00 | 75.00 | 103.00 | 77.00 | 71.00 | 36.00 | 58.00 | 16.00 | 34.00 | 59.00 | 88.00 | 63.00 | 76.00 | 60.00 | 56.00 | 70.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 67.00 | 75.00 | 103.00 | 77.00 | 71.00 | 36.00 | 58.00 | 16.00 | 34.00 | 59.00 | 88.00 | 63.00 | 76.00 | 60.00 | 56.00 | 70.00 |
| Current tax | 17.00 | 17.00 | 27.00 | 16.00 | 14.00 | -7.00 | 11.00 | 4.00 | 8.00 | 14.00 | 17.00 | 12.00 | 14.00 | 12.00 | 13.00 | 11.00 |
| Deferred tax | 2.00 | 4.00 | 3.00 | 9.00 | 8.00 | 16.00 | 7.00 | -0.00 | -5.00 | -9.00 | 8.00 | 3.00 | 4.00 | -13.00 | -13.00 | 8.00 |
| Tax expense | 20.00 | 21.00 | 30.00 | 25.00 | 22.00 | 10.00 | 17.00 | 4.00 | 3.00 | 5.00 | 25.00 | 14.00 | 18.00 | -1.00 | 0.00 | 18.00 |
| Profit for the period | 48.00 | 54.00 | 73.00 | 52.00 | 49.00 | 26.00 | 40.00 | 12.00 | 31.00 | 54.00 | 63.00 | 48.00 | 57.00 | 61.00 | 56.00 | 51.00 |
| Profit attributable to owners | 42.00 | 43.00 | 57.00 | 39.00 | 41.00 | 18.00 | 31.00 | 4.00 | 17.00 | 28.00 | 45.00 | 34.00 | 44.00 | 49.00 | 43.00 | 39.00 |
| Profit attributable to non-controlling interests | 6.00 | 12.00 | 16.00 | 14.00 | 8.00 | 8.00 | 10.00 | 8.00 | 14.00 | 26.00 | 18.00 | 14.00 | 13.00 | 12.00 | 13.00 | 13.00 |
| Other comprehensive income | -0.00 | -0.00 | -0.00 | 0.00 | -1.00 | 0.00 | -1.00 | 0.00 | -0.00 | -2.00 | 4.00 | -1.00 | 0.00 | -4.00 | 12.00 | 0.00 |
| Total comprehensive income | 47.00 | 54.00 | 73.00 | 53.00 | 48.00 | 26.00 | 39.00 | 13.00 | 30.00 | 52.00 | 66.00 | 48.00 | 57.00 | 57.00 | 68.00 | 51.00 |
| Earnings per share, basic | 4.77 | 5.31 | 7.01 | 4.86 | 3.78 | 1.70 | 2.81 | 0.36 | 1.51 | 2.57 | 4.06 | 3.10 | 3.93 | 4.31 | 3.75 | 3.39 |
| Earnings per share, diluted | 4.75 | 5.30 | 6.99 | 4.85 | 3.77 | 1.70 | 2.83 | 0.36 | 1.51 | 2.57 | 4.06 | 3.10 | 3.93 | 4.31 | 3.75 | 3.39 |
Annual results, as filed
| Line | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Revenue from operations | 811.00 | 1,066.00 | 1,602.00 | 1,475.00 | 1,437.00 | 2,365.00 |
| Other income | 26.00 | 15.00 | 9.00 | 30.00 | 11.00 | 18.00 |
| Total income | 837.00 | 1,081.00 | 1,610.00 | 1,505.00 | 1,448.00 | 2,384.00 |
| Cost of materials consumed | 469.00 | 692.00 | 768.00 | 693.00 | 937.00 | 1,442.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -130.00 | -322.00 | -64.00 | -79.00 | -332.00 | -119.00 |
| Employee benefit expense | 32.00 | 49.00 | 69.00 | 75.00 | 74.00 | 87.00 |
| Finance costs | 69.00 | 31.00 | 63.00 | 89.00 | 112.00 | 149.00 |
| Depreciation and amortisation | 52.00 | 60.00 | 71.00 | 80.00 | 102.00 | 140.00 |
| Other expenses | 246.00 | 351.00 | 398.00 | 405.00 | 358.00 | 431.00 |
| Total expenses | 737.00 | 860.00 | 1,304.00 | 1,264.00 | 1,251.00 | 2,129.00 |
| Profit before exceptional items and tax | 100.00 | 221.00 | 306.00 | 242.00 | 198.00 | 254.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 100.00 | 221.00 | 306.00 | 242.00 | 198.00 | 254.00 |
| Current tax | 18.00 | 39.00 | 73.00 | 34.00 | 44.00 | 52.00 |
| Deferred tax | 12.00 | 30.00 | 18.00 | 40.00 | -6.00 | -20.00 |
| Tax expense | 30.00 | 70.00 | 91.00 | 74.00 | 38.00 | 32.00 |
| Profit for the period | 70.00 | 152.00 | 217.00 | 167.00 | 160.00 | 222.00 |
| Profit attributable to owners | 70.00 | 152.00 | 181.00 | 129.00 | 93.00 | 170.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 36.00 | 39.00 | 67.00 | 52.00 |
| Other comprehensive income | -1.00 | -1.00 | -2.00 | -1.00 | 1.00 | 7.00 |
| Total comprehensive income | 70.00 | 151.00 | 215.00 | 167.00 | 161.00 | 229.00 |
| Earnings per share, basic | 8.56 | 15.22 | 20.91 | 11.89 | 8.50 | 15.09 |
| Earnings per share, diluted | 8.56 | 15.18 | 20.86 | 11.87 | 8.50 | 15.09 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 3,197.00 | 3,778.00 | 4,243.00 | 4,602.00 | 4,918.00 | 5,269.00 | 5,650.00 | 8,013.00 |
| Non-current assets | 1,540.00 | 1,667.00 | 1,954.00 | 2,375.00 | 2,597.00 | 2,696.00 | 2,835.00 | 4,285.00 |
| Current assets | 1,657.00 | 2,111.00 | 2,289.00 | 2,227.00 | 2,321.00 | 2,573.00 | 2,814.00 | 3,728.00 |
| Property, plant and equipment | 1,268.00 | 1,280.00 | 1,307.00 | 1,357.00 | 1,873.00 | 2,038.00 | 2,276.00 | 2,980.00 |
| Capital work-in-progress | 58.00 | 120.00 | 296.00 | 609.00 | 267.00 | 216.00 | 58.00 | 114.00 |
| Goodwill | 123.00 | 123.00 | 123.00 | 123.00 | 123.00 | 123.00 | 123.00 | 663.00 |
| Other intangible assets | 14.00 | 14.00 | 18.00 | 21.00 | 23.00 | 23.00 | 23.00 | 69.00 |
| Inventories | 938.00 | 931.00 | 1,011.00 | 1,055.00 | 1,272.00 | 1,452.00 | 1,492.00 | 1,775.00 |
| Trade receivables | 336.00 | 415.00 | 635.00 | 579.00 | 728.00 | 734.00 | 620.00 | 959.00 |
| Cash and cash equivalents | 51.00 | 188.00 | 234.00 | 250.00 | 40.00 | 113.00 | 413.00 | 378.00 |
| Total equity and liabilities | 3,197.00 | 3,778.00 | 4,243.00 | 4,602.00 | 4,918.00 | 5,269.00 | 5,650.00 | 8,013.00 |
| Equity | 1,905.00 | 2,508.00 | 2,591.00 | 2,931.00 | 2,970.00 | 3,082.00 | 3,449.00 | 4,630.00 |
| Equity share capital | 100.00 | 107.00 | 108.00 | 110.00 | 110.00 | 110.00 | 114.00 | 146.00 |
| Other equity | 1,693.00 | 2,265.00 | 2,332.00 | 2,651.00 | 2,673.00 | 2,740.00 | 3,083.00 | 3,188.00 |
| Total liabilities | 1,291.00 | 1,270.00 | 1,651.00 | 1,671.00 | 1,949.00 | 2,187.00 | 2,201.00 | 3,383.00 |
| Non-current liabilities | 541.00 | 459.00 | 497.00 | 356.00 | 348.00 | 379.00 | 265.00 | 767.00 |
| Current liabilities | 750.00 | 811.00 | 1,154.00 | 1,315.00 | 1,601.00 | 1,808.00 | 1,936.00 | 2,615.00 |
| Borrowings, non-current | 455.00 | 355.00 | 360.00 | 198.00 | 193.00 | 171.00 | 25.00 | 511.00 |
| Borrowings, current | 407.00 | 433.00 | 704.00 | 822.00 | 1,084.00 | 1,147.00 | 1,145.00 | 1,304.00 |
| Trade payables | 227.00 | 323.00 | 357.00 | 415.00 | 416.00 | 576.00 | 685.00 | 946.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 118.00 | 292.00 | -66.00 | 59.00 | -223.00 | -30.00 | 535.00 | 334.00 |
| Net cash from investing activities | -114.00 | -523.00 | -102.00 | -392.00 | -193.00 | -330.00 | -253.00 | -820.00 |
| Net cash from financing activities | -1.00 | 371.00 | 213.00 | 395.00 | 207.00 | 223.00 | 18.00 | 621.00 |
| Purchase of property, plant and equipment | 113.00 | 221.00 | 263.00 | 716.00 | 252.00 | 410.00 | 206.00 | 555.00 |
| Net increase in cash | 3.00 | 140.00 | 46.00 | 62.00 | -209.00 | -137.00 | 300.00 | 135.00 |
| con:CFO.BEFORE_TAX | 134.00 | 361.00 | -37.00 | 106.00 | -209.00 | 13.00 | 557.00 | 379.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 16.00 | 69.00 | 29.00 | 47.00 | 13.00 | 43.00 | 20.00 | 45.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | -2.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 4.00 | 13.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | -160.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-07-15 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 60.77 | 60.73 | 61.41 | 61.26 | 61.23 | 61.23 | 61.18 | 61.18 | 61.18 | 59.07 | 0.59 | 0.59 | 0.59 | 0.59 |
| Domestic institutions | 3.74 | 1.76 | 2.51 | 2.56 | 2.65 | 2.30 | 2.32 | 2.25 | 2.24 | 2.11 | 0.01 | 0.00 | 0.00 | 0.00 |
| Mutual funds | — | — | — | — | — | — | — | — | 1.90 | 1.78 | 0.01 | 0.00 | 0.00 | 0.00 |
| Insurance companies | 0.00 | 0.00 | 0.02 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Foreign institutions | 9.79 | 10.26 | 9.13 | 8.07 | 7.14 | 7.01 | 7.45 | 6.46 | 4.94 | 7.75 | 0.08 | 0.08 | 0.07 | 0.08 |
| Government | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 39.23 | 39.27 | 38.59 | 38.74 | 38.77 | 38.77 | 38.82 | 38.82 | 38.82 | 40.93 | 0.41 | 0.41 | 0.41 | 0.41 |
| Non-institutional | 25.69 | 27.25 | 26.95 | 28.11 | 28.97 | 29.47 | 29.05 | 30.11 | 31.65 | 31.06 | 0.32 | 0.33 | 0.34 | 0.33 |
| Shares outstanding | 107538864 | 107605249 | 109515228 | 109785896 | 109834688 | 109834688 | 109931337 | 109931337 | 109931337 | 113846223 | 113848310 | 113848310 | 113848310 | 113848310 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| KIRAN PALLAVI INVESTMENTS LLC | Promoter | Any other transaction, Dividend paid, Interest paid | 343,500,000.00 | 3 |
| TANGENT SCIENCE PRIVATE LIMITED | Associate of Subsidary Company | Advance, Any other transaction, Purchase of goods or | 307,520,000.00 | 4 |
| TANFAC INDUSTRIES LIMITED | Subsidiary company over which a ho | Dividend received, Purchase of goods or services | 134,610,000.00 | 2 |
| JAINAM INTERMEDIATES PVT LTD | Wholly-owned Subsidary | Purchase of goods or services | 65,670,000.00 | 1 |
| ARIL TRANSMODAL LOGISTIC PRIVATE LIMITED | Wholly-owned Subsidary | Any other transaction | 58,040,000.00 | 2 |
| ARIL FLUOROSPECIALITY PRIVATE LIMITED | Wholly-owned Subsidary | Interest received, Loan | 38,420,000.00 | 2 |
| ANAND DESAI | Managing Director | Dividend paid, Remuneration | 33,460,000.00 | 2 |
| MONA DESAI | Whole-time Director | Dividend paid, Remuneration | 28,110,000.00 | 2 |
| GOPAL AGRAWAL | Chief Executive Officer | Remuneration | 12,980,000.00 | 1 |
| DR. NILESH NAIK | Key Managerial Personnel | Any other transaction, Dividend paid, Remuneration | 10,080,000.00 | 3 |
| SHRADDHA ANAND DESAI | PROMOTER GROUP | Dividend paid | 5,840,000.00 | 1 |
| DR. ANUJ THAKAR | Whole-time Director | Dividend paid, Remuneration | 5,839,000.00 | 2 |
| AMIT KHURANA | Chief Financial Officer | Dividend paid, Remuneration | 5,832,000.00 | 2 |
| RAVI DESAI | Key Managerial Personnel | Dividend paid, Remuneration | 5,831,000.00 | 2 |
| REHASH INDUSTRIAL AND RESINS CHEMICALS PRIVATE LIMITED | Promoter | Dividend paid | 5,410,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-20 | Q1FY27 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2026-05-30 | Q4FY26 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2026-02-19 | Q3FY26 | OFFICER | Read the call |
| 2025-10-25 | Q2FY26 | Read the call | |
| 2025-08-19 | Q1FY26 | Read the call | |
| 2025-05-28 | Q4FY25 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2025-02-19 | Q3FY25 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2024-11-20 | Q2FY25 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2024-08-20 | Q1FY25 | ANUPAM RASAYAN INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2024-05-27 | Q4FY24 | Read the call | |
| 2024-02-15 | Q3FY24 | Read the call | |
| 2023-11-11 | Q2FY24 | ANUPAM RASAYAN INDIA LIMITED, INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2023-08-05 | Q1FY24 | ANUPAM RASAYAN INDIA LIMITED, INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2023-05-08 | Q4FY23 | ANUPAM RASAYAN INDIA LIMITED, INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2023-01-30 | Q3FY23 | ANUPAM RASAYAN INDIA LIMITED, INDIA LIMITED, RASAYAN INDIA LIMITED | Read the call |
| 2022-11-01 | Q2FY23 | Read the call | |
| 2022-07-29 | Q1FY23 | Read the call | |
| 2022-05-17 | Q4FY22 | Read the call | |
| 2021-08-24 | Q1FY22 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | So, if you were to map your CAPEX and the booking of revenue against your LOIs and contracts, you know, let's say over '24, '25, '26, how much of that… | As of December 31, 2024, we have completed INR650 crores of the planned INR670 crores capex. | — | Our current year CAPEX, we are expecting the CAPEX as we had guided in the last quarter as well that it would be Rs. | This coupled with expected cash flow from operations in the coming quarters will be sufficient for the planned capex. | So, I don't need any investment in capex for next two years. | May 24, 2025 one, where at some point, I might have to do a capex, but let's wait for that, and I'll come back as we finalize those numbers. | We are not envisaging any major capex in near future as current capacity is enough to take care of the near-term growth. |
| Capital allocation | — | Our fluorination chemistry portfolio, which got strengthened with the acquisition of Tanfac by ensuring uninterrupted supply of KF and HF around 3 yea… | I think you mentioned that Jayhawk's acquisition will be EPS accretive. | Two is the debt which I have taken for the acquisition of Tanfac shares. | And like the acquisition of Tanfac, we will acquire companies only if they are strategic and value accretive to Anupam. | — | May 24, 2025 from Tanfac and the acquisition of Tanfac as well. | May 25, 2026 In addition, we have successfully completed the acquisition of Jayhawk Fine Chemicals. |
| Costs | — | This initiative is expected to generate annual energy cost savings of approximately INR15 crores. | — | In the meantime, there is a tolerance level for each price or each raw material price, and once that raw material tolerance is breached, we immediatel… | So, for me, when I'm doing let's –say a 5-step process or a 10-step process, that at each step, there are a lot of raw materials and inputs which come… | So just can you please give a breakup of that raw material, WIP and finished goods inventories for stand-alone business for this financial year? | So Vishal bhai, as I understand, we have a pass-through clause with our customers, wherein any increase or decrease in raw material prices is immediat… | — |
| Debt and cash | So, my first question is on the working capital side. | And 1 more year of growth where I would have been able to liquidate my working capital and also increase my revenue, I would have been at 220 to 200 d… | Could you please give some clarity on how much improvement has been in your working capital days and what your targets are for FY27 and FY28? | So, there will be release of capital from the operations which would ensure our further growth and we do not expect any significant movement in terms … | May 03, 2023 strong cash flow from operations of around INR244 crores. | I understand the revenue de-growth and the macro behind there, but the sharp jump here in working capital, if you can put some light there across inve… | Also, majority of our customers are large multinational companies who had undertaken rationalization of supply chains and working capital at their end… | May 25, 2026 improving the working capital cycle and strengthening the supply chain. |
| Demand | Sir, my first question is from the LOIs and from customer's perspective, so we have seen that last quarter was an exceptional quarter in terms of the … | With the agrochemical demand picking up, coupled with higher contribution from pharma and polymer, and our growing strength in fluorination chemistry,… | — | Otherwise, I think there should be a cooling down going ahead because demand will be reduced at this time. | Looking at the project in pipeline, we have planned to develop our R&D team in FY '24 to 175 scientists. | So, my domestic from Agro to Pharma will be a move, because we are moving with a little bit of demand. | The agrochemical sector, which faced demand challenges in the earlier part of the year, has started to show signs of revival. | Yes, the performance -- the levers, as we have said, we have order book and Pharma and Polymer should be able to deliver a higher growth compared to a… |
| Guidance | In terms of, so we were earlier guiding FY '25 will have a big business. | February 14, 2025 Given the uptick in the demand momentum and projected offtake from our customers, we anticipate resuming our growth trajectory in th… | And especially we were looking at a Performance Materials business which we were expanding, which has expanded over the last year or two or more and w… | So, what is our current year CAPEX guidance? | In FY '24, we expect capex to be around INR350 crores to INR400 crores, our asset turns for FY '23 crossed 1x. | Yes, it has been a little lower than what we expected last year, which was 25.4% this year on a consolidated and 26.6% on a stand-alone. | We anticipate a gradual easing of working capital intensity with improved revenue in FY '26. | May 25, 2026 And also, one more thing that I want to guide or want to emphasize on, Ankur. |
| Margin | The competition intensity is pretty limited there because these are all imported from other geographies and hence, we have a strong ability to have a … | February 14, 2025 margin in this period. | — | EBITDA including other revenues was at Rs. | EBITDA was at INR1,416 million in Q4 FY '23 as compared to INR969 million in Q4 FY '22. | But any specific reason why both gross margin and EBITDA margin have contracted here? | EBITDA, including other income, was at INR150 crores in Q4 FY '25 as compared to INR105 crores in Q4 FY '24, up 43% Y-o-Y. | May 25, 2026 Profit after tax was at INR222 crores as compared to INR160 crores in FY25, translating to a PAT margin of 9% in FY26. Our business verti… |
| People | — | — | — | So, it will start ticking in let us say FY24 onwards and FY26 will be the peak year in terms of utilization, right? | What is your HF utilization, how many tons of HF do you utilize currently? | First is on is if a Tanfac and other fluorination businesses, if you can give some what is the current capacity utilization? | — | Also, if you look at this company is today having an operating capacity utilization of only 30% and we believe that, that can be very quickly enhanced… |
| Pricing | — | — | So could you please elaborate on why these European partners selected Anupam beyond process optimization and Tanfac integration, especially given Chin… | Customers have appreciated our request for changing the contract terms in terms of making the pricing at 6 months rather than yearly. | This growth augers well in the backdrop of a trending year in terms of supply chain issues, raw material pricing volatility, sticky inflation and othe… | So how much of that is volume and how much is pricing? | If you see that this AI is having a pricing of triple digit in dollar terms in kg. | — |
| Revenue growth | — | And I was expecting a revenue growth in the next year as well. | — | 2,743 million in Q4 FY21 registering a growth of 16% on YOY basis. | We have delivered a robust revenue growth of 20% plus in FY '23 driven by various contracts which we signed during FY '22 and '23. | So while our stand-alone sales have declined, so if that wasn't for the higher receivables, the actual top line would have declined by a much higher n… | May 24, 2025 While working capital remains a challenge due to the recent slowdown in sales, improving the working capital intensity is going to be one… | Coming to the top line on a pro forma basis, if I were to look at the pro forma basis business across the 4 companies, Anupam should be -- today is ar… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2023-08-05 | Q1FY24 | ANUPAM RASAYAN INDIA LIMITED | We have a contribution of over INR100 crores in the FY '23, and we expect these numbers to ramp up, and that number will ramp up fully. |
| 2023-08-05 | Q1FY24 | ANUPAM RASAYAN INDIA LIMITED | August 01, 2023 plan that we have, I think we should be around INR3,000 crores of revenue capability. |
| 2023-11-11 | Q2FY24 | ANUPAM RASAYAN INDIA LIMITED | On a concluding note, our order book remains strong, despite the challenging environment giving us a good visibility of robust growth for the current financial year, and we are positive on maintaining our guidance of 20% growth with similar margins. |
| 2024-08-20 | Q1FY25 | ANUPAM RASAYAN INDIA LIMITED | 80 to 100 crores of deferment, which we expect to come by the year end. |
| 2025-02-19 | Q3FY25 | ANUPAM RASAYAN INDIA LIMITED | February 14, 2025 Given the uptick in the demand momentum and projected offtake from our customers, we anticipate resuming our growth trajectory in the next financial year, targeting a 30% to 35% revenue increase in FY '26. |
| 2025-02-19 | Q3FY25 | ANUPAM RASAYAN INDIA LIMITED | And as Anand bhai already shared with you that we expect to grow at a rate of 30% to 35% in FY '26. |
| 2026-05-30 | Q4FY26 | ANUPAM RASAYAN INDIA LIMITED | So total, if I look at as of today delivered business on a pro forma basis, we should be looking at over INR 4,000 crores of revenue and an EBITDA of around about INR834 crores on a consol basis, I would say. |
| 2026-05-30 | Q4FY26 | ANUPAM RASAYAN INDIA LIMITED | I think going forward, we should be looking at around about 25% as a tax rate going forward. |
| 2026-08-20 | Q1FY27 | ANUPAM RASAYAN INDIA LIMITED | For Q1 FY27, consolidated cash profit stood at INR64 crores compared with INR56 crores in Q1 FY26. Working capital remained largely stable during the quarter, and we expect to see further improvement in FY27. As we have highlighted earlier, the business is becoming increasingly diversified towards pharma and performance materials, alongside the recovery in agro business. |